Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies
HORSHAM, Pa., May 2, 2023 – Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies. These investigational CD20-directed autologous CAR-Ts have demonstrated promising overall and complete response rates in Phase 1 studies in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL) in China, with the m...
Source: Johnson and Johnson - May 2, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
What Is Burkitt Lymphoma?
Title: What Is Burkitt Lymphoma?Category: Diseases and ConditionsCreated: 11/20/2015 12:00:00 AMLast Editorial Review: 7/29/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 29, 2021 Category: Cancer & Oncology Source Type: news
Novel Index IDs Prognosis in Adults With Burkitt Lymphoma
Validated international prognostic index stratifies patients according to low, intermediate, high risk (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 12, 2021 Category: Cancer & Oncology Tags: Oncology, Pathology, Journal, Source Type: news
Novel Index IDs Prognosis in Adults With Burkitt Lymphoma
FRIDAY, Feb. 12, 2021 -- The Burkitt lymphoma (BL) International Prognostic Index (BL-IPI) provides robust discrimination of survival and can be used for prognostication, according to a study published online Jan. 27 in the Journal of Clinical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 12, 2021 Category: Pharmaceuticals Source Type: news
New EPOCH for Adult Patients With Burkitt Lymphoma New EPOCH for Adult Patients With Burkitt Lymphoma
Dose-adjusted EPOCH-R chemotherapy offers similar outcomes in Burkitt lymphoma to high-dose therapy but with lower toxicity, making the traditional approach"unnecessary for cure," say US clinicians.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 11, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Phase III results show rituximab excels against pediatric Burkitt lymphoma
(University of Colorado Anschutz Medical Campus) Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2020 Category: International Medicine & Public Health Source Type: news
A new immunotherapeutic agent for children and adolescents with advanced lymphoma
(Comprehensive Cancer Centre Gustave Roussy) The excellent results of the phase III international paediatric study, Inter-B-NHL ritux 2010, have been published in the New England Journal of Medicine. It establishes a new standard treatment with an improved cure rate for children with advanced non-Hodgkin lymphoma, mainly Burkitt lymphoma. It supports the value of an immunotherapeutic agent, which was authorised in March 2020 by the European Commission for the treatment of a rare childhood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2020 Category: Cancer & Oncology Source Type: news
Study confirms effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma
Dose-adjusted EPOCH-R is already an option for diffuse large B-cell lymphomas and can be administered in an outpatient setting. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - May 26, 2020 Category: American Health Source Type: news
Study confirms effective, less toxic treatment option for adults with Burkitt lymphoma
(NIH/National Cancer Institute) In a new study, an alternative treatment regimen that is less toxic than standard dose-intensive chemotherapy was found to be highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status. In addition to being better tolerated, the regimen, called dose-adjusted (DA) EPOCH-R, is already an option for diffuse large B-cell lymphomas and can be administered in an outpatient setting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 26, 2020 Category: Cancer & Oncology Source Type: news
Study Findings Eliminate BCL-W as a Therapeutic Target for B-Cell Lymphomas
Researchers found that targeting BCL-W in Burkitt lymphoma and diffuse large B-cell lymphoma may not offer wide-ranging therapeutic benefit. (Source: CancerNetwork)
Source: CancerNetwork - February 10, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Burkitt Lymphoma
Title: Burkitt LymphomaCategory: Diseases and ConditionsCreated: 11/20/2015 12:00:00 AMLast Editorial Review: 8/15/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 15, 2018 Category: Cancer & Oncology Source Type: news
For Kids Like Me, Cancer Is Hard Enough
When I was a kid, I fell asleep in school a lot. The teachers didn’t scold me, and they kept the other kids from pointing and laughing. Because I wasn’t just tired — I was exhausted. I was drained. I was going through chemo.
When I was 7, I was diagnosed with Burkitt’s lymphoma, an aggressive cancer. The doctors at Boston Children’s Hospital gave me two months to live. I spent four years in and out of aggressive treatments, missing second and third grade, fighting for my life when I should’ve been playing hockey.
But slowly, I recovered. My community stood by my family, and my dad&...
Source: Healthy Living - The Huffington Post - June 26, 2017 Category: Consumer Health News Source Type: news
In sub-Saharan Africa, cancer can be an infectious disease
In a new report, a researcher shows that mothers who contract malaria during pregnancy may have children with increased risk of Burkitt ' s lymphoma. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 25, 2016 Category: Science Source Type: news
In sub-Saharan Africa, cancer can be an infectious disease
(University of Colorado Anschutz Medical Campus) University of Colorado Cancer Center researcher shows that mothers who contract malaria during pregnancy may have children with increased risk of Burkitt's lymphoma. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 25, 2016 Category: Biology Source Type: news
Jimmy Carter Takes Sweet Selfies With Young Fellow Cancer Survivor
This was a meeting of some awesome minds.
Cancer survivor Carter Beckhard-Suozzi’s dreams came true earlier this week when he met former President Jimmy Carter, thanks to the Make-A-Wish Foundation.
The meeting took place at the Carter Center in Atlanta and was hugely significant to the 10-year-old boy, who is in remission from Burkitt’s Lymphoma, and his family, according to a press release.
“It’s just been incredibly uplifting to be able to experience a trip like this and be free from everything Carter has been going through,” Carter’s mother Jane Beckhard-Suozzi said...
Source: Healthy Living - The Huffington Post - July 14, 2016 Category: Consumer Health News Source Type: news
